Search
News & Events
Outstanding mentor named Eureka prize finalistLeading infectious diseases researcher, Clinical Associate Professor Deborah Lehmann AO, has been named a finalist for the Australian Museum Eureka Prizes for her work training and mentoring a new generation of researchers.
News & Events
Major grant empowers community voices to drive reduction in skin infectionsAboriginal community members throughout the Kimberley will take a lead role in driving healthy skin messages within their own communities thanks to a major funding boost to The Kids Research Institute Australia’s SToP Trial.
News & Events
National guideline to tackle record rates of skin infectionResearchers have developed the first National Healthy Skin Guideline to address record rates of skin infections in Australia’s Indigenous communities.
News & Events
New RHD research collaboration with Danila Dilba Health ServiceThe Kids Research Institute Australia and Menzies School of Health Research have joined forces with Danila Dilba Health Service to look at improving treatment for RHD.
News & Events
Inaugural Winner of the Deborah Lehmann Research AwardCongratulations goes to Celestine Aho, the inaugural winner of the $30,000 Deborah Lehmann Research Award.
News & Events
$2 million grant to develop diagnostic tool for rheumatic feverThe Kids Research Institute Australia & Menzies School of Health Research will lead an international project to develop a diagnostic tool for acute rheumatic fever.
Research
Adverse event reports of anaphylaxis after Comirnaty and Vaxzevria COVID-19 vaccinations, Western Australia, 22 February to 30 June 2021Within the first 4 months of the Western Australian COVID-19 immunisation programme, 49 suspected anaphylaxis cases were reported to the vaccine safety surveillance system. Twelve reports met Brighton Collaboration case definition, corresponding to rates of 15.9 and 17.7 per million doses of Vaxzevria and Comirnaty administered respectively.
Research
Influenza hospitalizations in Australian children 2010–2019: The impact of medical comorbidities on outcomes, vaccine coverage, and effectivenessChildren with comorbidities are at greater risk of severe influenza outcomes compared with healthy children. In Australia, influenza vaccination was funded for those with comorbidities from 2010 and all children aged <5 years from 2018. Influenza vaccine coverage remains inadequate in children with and without comorbidities.
Research
Variants of Streptococcus pneumoniae Serotype 14 from Papua New Guinea with the Potential to Be Mistyped and Escape Vaccine-Induced ProtectionStreptococcus pneumoniae (the pneumococcus) is a human pathogen of global importance, classified into serotypes based on the type of capsular polysaccharide produced. Serotyping of pneumococci is essential for disease surveillance and vaccine impact measurement.
Research
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trialWe previously reported the efficacy of the adjuvanted-protein COVID-19 vaccine candidate S-Trimer (SCB-2019) in adults who showed no evidence of previous exposure to SARS-CoV-2. In this study, we aimed to investigate the extent of protection afforded by previous exposure to SARS-CoV-2 on subsequent COVID-19 infection, as well as the efficacy, safety, and reactogenicity of SCB-2019 in participants who were enrolled in the Study.